MetaCap

Relmada Therapeutics (RLMD) vs ARS Pharmaceuticals (SPRY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Relmada Therapeutics (RLMD) has outperformed ARS Pharmaceuticals (SPRY) over the past year, losing 38.6% versus a loss of 61.0%. Over five years, SPRY leads with a -58.8% price change compared with -86.1% for RLMD. ARS Pharmaceuticals is the larger company by market cap ($297.6 million vs $279.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RLMD-38.64%SPRY-61.00%
+92%+9%-73%
Nov 21, 20251 yearNov 20, 2026
RLMD-87.15%SPRY-63.99%
+132%+11%-110%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RLMD versus SPRY key metrics
MetricRLMDSPRY
Share price$2.62$2.96
Market cap$279.54M$297.56M
1-day change-15.76%-11.90%
YTD return-45.76%-74.59%
1-year return-38.64%-61.00%
5-year return-86.09%-58.83%
EPS (TTM)$-0.73$-2.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$84.28M
Revenue growth (YoY)—-5.46%
Net income (latest FY)$-57.39M$-171.30M
Operating margin—-212.92%
Net margin—-203.25%
52-week high$8.00$13.15
52-week low$2.60$2.44
Distance from 52-week high-67.25%-77.49%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+310.31%+474.32%
Average volume1.45M1.83M
Shares outstanding106.69M100.53M
Employees17203
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RLMD has outperformed SPRY by 22.4 percentage points over the past year.

About Relmada Therapeutics

RLMD stock →

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

About ARS Pharmaceuticals

SPRY stock →

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.

Health Care · Biotechnology: Pharmaceutical Preparations · 203 employees

RLMD vs SPRY FAQ

Which is bigger, Relmada Therapeutics or ARS Pharmaceuticals?

ARS Pharmaceuticals (SPRY) is larger, with a market capitalization of $297.56M compared with $279.54M for Relmada Therapeutics (RLMD).

Which stock has performed better over the past year, RLMD or SPRY?

RLMD returned -38.64% over the past 12 months, compared with -61.00% for SPRY (price return, excluding dividends). Past performance does not predict future results.

Are Relmada Therapeutics and ARS Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons